GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (FRA:135A) » Definitions » Cyclically Adjusted Price-to-FCF

SCYNEXIS (FRA:135A) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to 2014. Start your Free Trial

What is SCYNEXIS Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


SCYNEXIS Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for SCYNEXIS's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Cyclically Adjusted Price-to-FCF Chart

SCYNEXIS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SCYNEXIS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SCYNEXIS's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Cyclically Adjusted Price-to-FCF falls into.


;
;

SCYNEXIS Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

SCYNEXIS's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, SCYNEXIS's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.14/134.9266*134.9266
=-0.140

Current CPI (Mar. 2025) = 134.9266.

SCYNEXIS Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -6.275 100.684 -8.409
201509 -3.695 100.392 -4.966
201512 -3.973 99.792 -5.372
201603 -5.794 100.470 -7.781
201606 -5.485 101.688 -7.278
201609 -2.608 101.861 -3.455
201612 -1.789 101.863 -2.370
201703 -2.478 102.862 -3.250
201706 -2.545 103.349 -3.323
201709 -1.625 104.136 -2.105
201712 -1.519 104.011 -1.970
201803 -1.987 105.290 -2.546
201806 -1.516 106.317 -1.924
201809 -1.132 106.507 -1.434
201812 -1.126 105.998 -1.433
201903 -1.166 107.251 -1.467
201906 -1.289 108.070 -1.609
201909 -1.408 108.329 -1.754
201912 -1.836 108.420 -2.285
202003 -1.306 108.902 -1.618
202006 -0.786 108.767 -0.975
202009 -0.626 109.815 -0.769
202012 -1.090 109.897 -1.338
202103 -0.030 111.754 -0.036
202106 -0.368 114.631 -0.433
202109 -0.518 115.734 -0.604
202112 -0.853 117.630 -0.978
202203 -0.438 121.301 -0.487
202206 -0.406 125.017 -0.438
202209 -0.479 125.227 -0.516
202212 -0.453 125.222 -0.488
202303 -0.370 127.348 -0.392
202306 1.375 128.729 1.441
202309 0.243 129.860 0.252
202312 -0.148 129.419 -0.154
202403 -0.076 131.776 -0.078
202406 -0.208 132.554 -0.212
202409 0.014 133.029 0.014
202412 -0.194 133.157 -0.197
202503 -0.140 134.927 -0.140

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SCYNEXIS  (FRA:135A) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


SCYNEXIS Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


SCYNEXIS Business Description

Industry
Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

SCYNEXIS Headlines

No Headlines